AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.009

-0.001-10.00%

Volume:414.93K

Turnover:4K

Market Cap:39.04M

PE:-0.47

High:0.010

Open:0.010

Low:0.009

Close:0.010

52wk High:0.040

52wk Low:0.009

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.10

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.018

ROE:-174.71%

ROA:-49.84%

PB:1.58

PE(LYR):-0.49

Loading ...

Overview Company News Filings

Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors

THOMSON REUTERS

Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review

Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution

THOMSON REUTERS

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors

THOMSON REUTERS

Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis

THOMSON REUTERS

Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026

THOMSON REUTERS

Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial

MT Newswires Live

Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial

THOMSON REUTERS

Radiopharm Theranostics Shareholders Vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari Director SPP Allocations at Sept. 11 Meeting

Radiopharm Theranostics Ltd-Share Purchase Plan - NOW Open

THOMSON REUTERS

Radiopharm Theranostics - Plans to Initiate Phase 3 Registrational Trial of Rad 101 in Q4 2026

THOMSON REUTERS

Radiopharm Theranostics - Closing Cash at End of Quarter $4.10 Mln

THOMSON REUTERS

Radiopharm Theranostics Plans Phase 3 Registrational Trial of Imaging Agent Rad101 in Q4 2026

Press Release: Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Approvals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.009,"timestamp":1787897520000,"preClose":0.01,"halted":0,"volume":414931,"delay":0,"changeRate":-0.10000000000000009,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.019034,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"08-28 16:12:00 AEST","open":0.01,"high":0.01,"low":0.009,"amount":4018,"amplitude":0.1,"askPrice":0.01,"askSize":152000,"bidPrice":0.009,"bidSize":14552898,"shortable":3,"etf":0,"ttmEps":-0.019034,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":0.09938063354646137,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":90000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787897387782}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-49.84%","roe":"-174.71%","lyrEps":-0.018424,"volumeRatio":0.09938063354646137,"shares":4337549000,"dividePrice":0,"high":0.01,"amplitude":0.1,"preClose":0.01,"low":0.009,"week52Low":0.009,"pbRate":"1.58","psRate":"3.09","week52High":0.04,"institutionHeld":0,"latestPrice":0.009,"committee":0.979327,"eps":-0.019034,"divideRate":0,"volume":414931,"delay":0,"ttmEps":-0.019034,"open":0.01,"prevYearClose":0.025,"prevWeekClose":0.009,"prevMonthClose":0.014,"prevQuarterClose":0.019,"fiveDayClose":0.01,"twentyDayClose":0.014,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662051887","title":"Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051887?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051884","title":"Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051881","title":"Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051881?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718764","title":"Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:00","pubTimestamp":1787742001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA86WLSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286639","title":"Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286639","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286639?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:03","pubTimestamp":1787223813,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC reviewRadiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL8L5MBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BCDF","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","LU2210149790.SGD","NDAQ","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","RAD.AU","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BK4588","IE00B64PRP62.GBP","IE00BQXX3F31.USD","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660728687","title":"Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2660728687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660728687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332286","title":"Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332286?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286382","title":"Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286382?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482805","title":"Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482805","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482805?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966297,"startTime":"0","endTime":"0","summary":"Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics entered a partnership with Siemens Healthineers to manufacture, distri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL3jXZZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BCDF","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","RAD.AU","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK7067","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828634","title":"Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828634?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828624","title":"Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828624?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101432","title":"Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101432?lang=en_us&edition=fundamental","pubTime":"2026-08-17 11:33","pubTimestamp":1786937616,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  will meet with the US Food and Drug Administration  on Oct. 1 to seek alignment on the design of a phase 3 trial to evaluate its RAD101 imaging agent in patients with suspected recurrence of brain metastases following radiotherapy, according to a Monday filing with the Australian bourse.The meeting will focus on the trial's design criteria, including the number of patients to be enrolled and the primary and secondary endpoints, per the filing.The FDA will also review data from a phase 2b trial of RAD 101, which showed 93% concordance between MRI and PET imaging of brain metastases in the targeted patient population, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","RAD.AU","BK7067","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103689","title":"Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103689?lang=en_us&edition=fundamental","pubTime":"2026-08-17 07:02","pubTimestamp":1786921352,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nTUE7QS9KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659548111","title":"Radiopharm Theranostics Shareholders Vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari Director SPP Allocations at Sept. 11 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2659548111","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659548111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:05","pubTimestamp":1786622701,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics shareholders vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari director SPP allocations at Sept. 11 meetingRadiopharm Theranostics shareholders vote Sept. 11, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLb5WwMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657566431","title":"Radiopharm Theranostics Ltd-Share Purchase Plan - NOW Open","url":"https://stock-news.laohu8.com/highlight/detail?id=2657566431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657566431?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:38","pubTimestamp":1786059496,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUEQ4HGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686203","title":"Radiopharm Theranostics - Plans to Initiate Phase 3 Registrational Trial of Rad 101 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686203?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495776,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368915","title":"Radiopharm Theranostics - Closing Cash at End of Quarter $4.10 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368915?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686303","title":"Radiopharm Theranostics Plans Phase 3 Registrational Trial of Imaging Agent Rad101 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686303","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686303?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:01","pubTimestamp":1785495703,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics plans Phase 3 registrational trial of imaging agent RAD101 in Q4 2026Radiopharm Theranostics reported Phase 2b results for imaging agent RAD 101 in recurrent brain metastases, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLbx6scR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","BK7067","SG9999014005.SGD","BCDF","LU2210149790.SGD","NDAQ","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","RAD.AU","SG9999014013.SGD","BK4585","BK4112","IE00BKPKM429.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","BK4183","GDOC","NVIB","RAD.AU","IE0009354923.USD","RADX","ODD","BK7067","BK4139","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866708","title":"Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866708","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655866708?lang=en_us&edition=fundamental","pubTime":"2026-07-29 00:00","pubTimestamp":1785254401,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics announces extraordinary general meeting for shareholder approvalsRadiopharm Theranostics will hold an extraordinary general meeting in Australia on about Sept. 11, 2026.Shareho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL3Jkm6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}